Coverage
-
June 09, 2022
Federal Trade Commission staffers pressed their bid to block Illumina's $8 billion reacquisition of cancer testing outfit Grail during closing arguments, as the agency's administrative law judge questioned whether getting the case wrong could cost lives.
2 other articles on this case.
View all »